Compare NEXN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXN | LCTX |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 407.7M |
| IPO Year | 2021 | N/A |
| Metric | NEXN | LCTX |
|---|---|---|
| Price | $5.96 | $1.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $12.00 | $4.25 |
| AVG Volume (30 Days) | 390.1K | ★ 1.2M |
| Earning Date | 03-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | $10,816,000.00 |
| Revenue This Year | $5.43 | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | $9.55 | ★ N/A |
| Revenue Growth | 7.80 | ★ 24.05 |
| 52 Week Low | $5.72 | $0.37 |
| 52 Week High | $12.60 | $2.09 |
| Indicator | NEXN | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.44 | 48.58 |
| Support Level | $5.72 | $1.64 |
| Resistance Level | $6.90 | $1.79 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 20.33 | 44.23 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.